Citadel Advisors
OMIC

Citadel Advisors’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Citadel Advisors’s Portfolio OMIC Stock Details OMIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,897
Closed -$60.1K – 15756
2024
Q1 		$60.1K Buy
3,897
+2,361
+154% +$36K ﹤0.01% 11997
2023
Q4 		$21.2K Sell
1,536
-591
-28% -$6.99K ﹤0.01% 12576
2023
Q3 		$24.3K Buy
2,127
+1,182
+125% +$22K ﹤0.01% 12465
2023
Q2 		$23.5K Buy
945
+728
+335% +$21.3K ﹤0.01% 12590
2023
Q1 		$7.88K Buy
217
+54
+33% +$3.31K ﹤0.01% 13694
2022
Q4 		$9.81K Sell
163
-1,780
-92% -$119K ﹤0.01% 13661
2022
Q3 		$145K Buy
1,943
+791
+69% +$82.6K ﹤0.01% 10743
2022
Q2 		$132K Sell
1,152
-13,798
-92% -$1.62M ﹤0.01% 11116
2022
Q1 		$2.83M Buy
14,950
+12,979
+658% +$3M ﹤0.01% 5324
2021
Q4 		$684K Sell
1,971
-763
-28% -$296K ﹤0.01% 8901
2021
Q3 		$918K Sell
2,734
-5,768
-68% -$2.96M ﹤0.01% 8374
2021
Q2 		$7.01M Buy
+8,502
New +$6.59M ﹤0.01% 3735

Other funds holding OMIC

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
QM
QVIDTVM Management The Woodlands, Texas $81.4M AUM 2.94% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Citadel Advisors's OMIC Position: Q2 2024 in Review

Citadel Advisors sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q2 2024, closing a stake of 3,897 shares — an estimated $60.1K sold.

Citadel Advisors first reported a position in OMIC in Q2 2021 and held it in 12 quarters. The position peaked at $7.01M in Q2 2021. 24 funds tracked by Wall St. Rank hold OMIC as of Q2 2024.

  • Citadel Advisors reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 3,897 Singular Genomics Systems, Inc. Common Stock shares in Q2 2024, an estimated $60.1K.
  • Citadel Advisors first reported a position in Singular Genomics Systems, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • Citadel Advisors's Singular Genomics Systems, Inc. Common Stock position peaked at $7.01M in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.